Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — H1 2019/20 Earnings Presentation
77 slides from Coloplast A/s Class B's earnings presentation, May 2020
Slide 1: Leading intimate healthcare – Roadshow presentation H1 2019/20
Making life easier_ Leading intimate healthcare Roadshow presentation H1 2019/20 Making life easier Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: An update on how Coloplast is navigating the COVID-19 pandemic
An update on how Coloplast is navigating the COVID-19 pandemic • Three key priorities: keeping our people safe, continuing to serve our customers and maintaining business operations • Global guidelines, safety measures and contingency plans implemented • Support consumers with dependable delivery of
Slide 4: Continued solid performance in Q2 impacted by COVID-19 outbreak and stock building
Continued solid performance in Q2 impacted by COVID-19 outbreak and stock building in primarily Europe Q2 Highlights Revenue growth +9% • Organic growth of 9% and 10% reported growth in DKK Reported revenue (DKKm) +8% • Chronic Care delivered a strong underlying growth in Q2 ex-China Organic growth
Slide 5: Solid growth in Chronic Care in Q2 lifted by stock building in Europe
Solid growth in Chronic Care in Q2 lifted by stock building in Europe; China & Interventional Urology negatively impacted Q2 19/20 revenue by business area Q2 19/20 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of orga
Slide 6: Ostomy Care grew 10% organically in Q2
Ostomy Care grew 10% organically in Q2, positively impacted by stock building in primarily Europe due to COVID-19 Ostomy Care performance Comments • H1 organic growth of 9% (reported growth 10%). Q2 organic growth 10 10 of 10% (reported growth 10%) 9 9 9 • Sales growth in Q2 was positively impacted
Slide 7: Continence Care grew 12% organically in Q2
Continence Care grew 12% organically in Q2, positively impacted by stock building in primarily Europe due to COVID-19 Continence Care performance Comments 12 • H1 organic growth of 9% (reported growth 9%). Q2 organic growth of 12% (reported growth 12%) 10 • Sales growth in Q2 was positively impacted
Slide 8: Interventional Urology grew 3% organically in Q2
Interventional Urology grew 3% organically in Q2, adversely impacted by COVID-19 and a decline in elective procedures Interventional Urology performance Comments • H1 organic growth of 6% (8% reported growth). Q2 organic growth 14 14 14 of 3% (5% reported growth) 12 11 • Growth in H1 was driven by t
Slide 9: Wound Care delivered negative 2% organic growth in Q2
Wound Care delivered negative 2% organic growth in Q2 due to hospital closures and other restrictions in China Wound & Skin Care performance Comments • H1 organic growth of 7% in Wound & Skin Care (8% reported growth). Q2 organic growth of 4% in Wound & Skin Care (5% reported growth) 11 11 • Organic
Slide 10: Q2 2019/20 reported revenue grew 10% driven by solid organic growth of 9%
Q2 2019/20 reported revenue grew 10% driven by solid organic growth of 9% Comments Revenue development • Q2 2019/20 reported revenue increased by DKK 442m (DKKm) or 10% compared to Q2 2018/19 396 26 4,823 • The majority of growth was driven by organic growth contributing DKK 396m or 9% to reported r
Slide 11: EBIT grew 15% in Q2
EBIT grew 15% in Q2 driven by underlying operating leverage and lower commercial spending during the COVID-19 outbreak Comments EBIT margin development (%) • Q2 gross margin of 68% in DKK compared to 67% last year 0.1 -0.5 • Positive impact from operating leverage driven by revenue growth, 0.4 GOP4
Slide 12: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments • Free cash flow in H1 2019/20 was DKK 1,181m, up 18% compared to DKK 1,004m in H1 2018/19 98 99 98 • Adjusted for the positive impact of DKK 95m related to the 93 96 92 reclassification of lease payments following the a
Slide 13: Financial guidance for FY 2019/20 – updated capex guidance
Financial guidance for FY 2019/20 – updated capex guidance Guidance 2019/20 Guidance 2019/20 (DKK)* Key assumptions • The situation in Interventional Urology gradually normalises during H2 • The situation in China in Ostomy Care and Wound Care gradually normalises during H2 Sales growth 4-6% • The l
Slide 14: Coloplast establishes Sponsored Level 1 ADR programme in US
Coloplast establishes Sponsored Level 1 ADR programme in US Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Colo
Slide 15: Introduction to Coloplast
Leading intimate healthcare Introduction to Coloplast
Slide 16: Coloplast has four business areas all with global sales presence
Coloplast has four business areas all with global sales presence Group revenue 2018/19 by segment Group revenue 2018/19 by geography X = Coloplast’s global market position Emerging markets 17% Ostomy Care Continence 40% Care 36% #1 DKK DKK 17.9bn #1 Other 17.9bn European developed markets markets 59
Slide 17: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? People who have had their intestine redirected to an SenSura® Mio opening in the abdominal wall Ostomy bag Ostomy Care People in need of bladder or bowel management SpeediCath® Continence Flexible male
Slide 18: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKKbn) Organic growth (%) 10 10 9 8 8 8 8 7 7 7 7
Slide 19: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends Drivers Limiters Earlier detection and Growing elderly Surgical and cure, eventually 1 Demographics population increases 1 medical trends reduces addressable customer base for market for Coloplast Coloplast products treatment products Ex
Slide 20: Strong market positions in Europe and commercial potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Developed Emerging Ostomy Continence Urology Wound Care Addressable market 18-19n 13-14bn 12-13bn 22-24bn 4-5% 5-6% 3-5% 2-4% Size in DKK Growth in % Coloplast 40 - 50% 45 - 55% 20 - 25% 5 - 10% regi
Slide 21: Building the consumer healthcare company of the future
We are building what we believe is the consumer healthcare company of the future Superior Clinical Consumer Payer products & preference preference preference innovation Care, DtC & Direct Data and digital tools Page 21
Slide 22: LEAD20 strategy will drive revenue and earnings growth across 4 themes
Coloplast’s LEAD20 strategy will drive revenue and earnings growth across 4 major themes 1 Superior products & innovation 2 Unique user focused market approach 3 Unparalleled efficiency 4 Strong leadership development Page 22
Slide 23: Long-term guidance for the LEAD20 strategy period
Long-term guidance for the LEAD20 strategy period aimed at accelerating growth and long-term value creation Revenue growth EBIT margin annual organic constant currencies 7–9% >30% Page 23
Slide 24: Investment strategy has a balanced approach
To fuel growth & sustain long-term competitive advantage, our investment strategy has a balanced approach Up to 2% of sales invested annually across… …functions …geographies …and time horizons 15/16-18/19 15/16-18/19 Short term: Sales force, marketing and infrastructure • Optimize and expand our com
Slide 25: Global Coloplast Care and DtC presence
Our global Coloplast Care and DtC presence enables us to support users across countries and business areas Over 1M consumers in our database Over 1M conversations with users across the globe Over 30 countries with a consumer setup New Bowel Care program implemented in 2018 Coloplast Care & DTC offer
Slide 26: Clinical Performance Program to tackle the biggest issues users face
We have initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face What really matters to people using catheters? What really matters to people living with a stoma? 45 %* of users describe UTIs are their 93 % worry about leakage2 greatest challenge in life1 * Peo
Slide 27: Digitalization of new products
Through digitalization of new products, we will take the next step towards our mission of making life easier for our users Digitalization in product development as first important milestone Payers Digitalization • We have a mission of making life easier Direct for people with intimate healthcare Glo
Slide 28: Burden of illness study in Germany shows significant payer costs
Example: Results from a burden of illness study in Germany show significant payer costs linked to ostomates Data Total cost per year Total cost split ostomates(1) EUR Inpatient Stoma products German claims database Colostomy, ileostomy and nursing 2.5m beneficiaries x3 and urostomy Outpatient Other
Slide 29: Global Operation Plan 4 supports LEAD20
Global Operation Plan 4 aims to support LEAD20 through continued unparalleled efficiency and financial discipline Global Operations Plan 4 1. Reduction of manufacturing in Denmark EBIT margin contribution, bps Manufacturing FTE’s in Denmark, Ultimo FY GOP 3 GOP 4 700 600 50 500 375 21% 225 100 Salar
Slide 30: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional investments within distribution and R&D Gross margin development, in % of revenue Cost item Development, in % of revenue + 0.5%-points 28.5 28.1 28.1 28.7 29.0 28-30 Distribution 68.5 68.3 68.1 67.3 67.7 - 0.1%-points 4.
Slide 31: Global Business Support and IT landscape enables scaling
A global Business Support and IT landscape enables Coloplast to scale faster and more efficiently Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% IT infrastructure Finance/ Master Data Global Business & support accountin
Slide 32: We will continue to deliver strong free cash flows
We will continue to deliver strong and attractive free cash flows … Taxation Net working capital CAPEX(2) Reported tax rate, % Net working capital in % revenue Depreciation in % of revenue CAPEX DKKm CAPEX in % of revenue 4.4 28 24 24 25 24 3.8 4-5% 23 24 23 23 23 23 23 2.5 2.8 649 685 669 690 617 1
Slide 33: Attractive cash returns despite large investments
…and continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Comments • Coloplast returns excess liquidity to Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) shareholde
Slide 34: Key highlights from 2018/19 Corporate Responsibility initiatives
Key highlights from 2018/19 Corporate Responsibility initiatives Empowering People Acting respectfully Minimising footprint Our Access to Healthcare programme has New target to increase share of diverse teams Achieved 100% electricity from supported 62 projects since 2007. (gender, generation, natio
Slide 35: Coloplast can continue to deliver stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... 32% Comments • Stable market trends in our Chronic Care business • Strong Coloplast Care retention program and innovative DtC 10% activities 8% 9% • Increased focus on growing the business outside Europe • Ad
Slide 36: Appendices
Leading intimate healthcare Appendices
Slide 37: The Coloplast share (COLO'B-KO)
The Coloplast share (COLO’B-KO) Share Capital Ownership Coloplast share listed on Nasdaq Copenhagen since 1983 ~230 billion DKK (~34 billion USD) market cap @ ~1,080 DKK 10% per share (incl. A shares) 5% 2% Two share classes: 46% • 18m A shares carry 10 votes (family) • 198m B shares carry 1 vote (f
Slide 38: Capital structure
Capital structure Comments Net interest bearing debt • Overall policy is that excess liquidity is returned to shareholders through a combination of dividends and share buy- 0.1x 0.1x 0.1x -0.3x -0.2x backs • Interest bearing debt will be raised in connection with a major acquisition or other special
Slide 39: H1 revenue by business area and geography
Solid growth in Chronic Care in Europe in H1 lifted by stock building; Interventional Urology and China negatively impacted H1 19/20 revenue by business area H1 19/20 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of or
Slide 40: H1 2019/20 reported revenue grew 9%
H1 2019/20 reported revenue grew 9% driven by solid organic growth of 8% Comments Revenue development • H1 2019/20 reported revenue increased by DKK 813m (DKKm) or 9% compared to H1 2018/19 83 9,535 • The majority of growth was driven by organic growth 730 contributing DKK 730m or 8% to reported rev
Slide 41: EBIT grew 14% in H1 2019/20
EBIT grew 14% in H1 2019/20 Comments EBIT margin development (%) • Gross margin of 68% in DKK compared to 67% last year 0.4 -0.3 • Positive impact from operating leverage driven by revenue growth, GOP4 and the closure of the Thisted factory in June 2019 31.6 0.4 31.3 • Negative impact from product m
Slide 42: Key Value Ratios
Key Value Ratios Profitability drivers Free Cash Flow drivers 31.9 32.7 32.3 36.6 36.3 36.0 31.7 32.0 34.7 34.6 28.1 28.7 29.0 28.1 29.1 25.2 23.8 23.4 23.6 23.7 3.8 4.0 4.0 4.2 3.8 5.0 4.4 4.4 4.1 3.8 3.5 3.7 3.9 3.9 3.7 15/16 16/17 17/18 18/19 YTD 19/20 15/16 16/17 17/18 18/19 YTD 19/20 Admin-to-S
Slide 43: Revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology 9 7,166 10 6,291 6,643 13 5,935 8 9 9 10 10 10 8 6 9 7 7 3,827 10 10 6 8 7 67 9 6 5 6 1,740 1,970 1,497 1,641 1,042 15/16 16/17 17/18 18/19 YTD 19/20 15/16 16/17 17/18 18/19 YTD 19/20 Continence Care Wound & Skin Care
Slide 44: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 9,941 10,573 9,213 9,394 15 16 14 8 11 5,591 8 11 10 6 5 6 6 3,642 3,791 4,380 7 3,177 2,351 4 2 5 6 6 4 15/16 16/17 17/18 18/19 YTD 19/20 15/16 16/17(1) 17/18 18/19 YTD 19/20 Emerging Markets Coloplast group 17,939
Slide 45: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Chronic Care Interventional Urology Wound & Skin Care Ostomy and Continence Care 60 39 38 39 39 40 39 40 58 57 59 37 55 34 35 2,083 2,047 2,168 1,928 1,901 187 194 197 170 179 235 250 248 228 225 Q2 18/19 Q3 18/19 Q4 18/19 Q1 19/20 Q2 19
Slide 46: Exchange rate exposure FY 2019/20 and hedging policy
Exchange rate exposure FY 2019/20 and hedging policy Revenue FX exposure 2019/20(1) 12 months exposure from 10% initial exchange rate drop(1) Other 15% -390 USD -170 EUR CNY, JPY, AUD, BRL & ARS 12% 39% -270 GBP -170 HUF 0 14% 110 GBP 20% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 47: Mesh litigation timeline
Mesh litigation timeline Jan. 31, 2019: Verdict vs Ethicon PA State Court: USD 41M Jan. 21, 2020: Dec. 14, 2017: Verdict for Ethicon April 28, 2017: (DKK 354.3M) Sept. 9, 2014: Verdict vs Ethicon FL Federal Court: Verdict vs Ethicon NJ State Court: Verdict vs BSC Dec. 24, 2015: PA State Court: USD 1
Slide 48: US Mesh litigation – overview of current financial impact
US Mesh litigation – Overview of current financial impact P&L Balance Cash flow Assets Actual/Expected cash flow, DKKbn 13/14 14/15 15/16 16/17 17/18 18/19 19/20 Restricted cash, DKKbn 0.5 0.5 EBIT (before special items) 4,147 4,535 4,846 5,024 5,091 5,556 3,014 Special items -1,000 -3,000 - 750 0 0
Slide 49: Health reform landscape
Health reform landscape Europe Rest of World • France: Reimbursement pressure on OC, CC and WC • U.S.: Healthcare reform implementation ongoing • Greece: Reimbursement pressure on all BAs • Argentina: Macroeconomic challenges • Germany: Reimbursement pressure on OC and CC • Brazil: Macroeconomic and
Slide 50: CARE helps increase retention and product compliance
CARE helps us increase retention and improve product compliance for in excess of 500,000 enrolled consumers We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content
Slide 51: DtC marketing program reaches into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our service …and with the reach we get several benefits and product offering… Expose innovative products Ensure product accessibility Ensure successful experience Page 51
Slide 52: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Payer Reimbursement price Distribution Prescription & Insurance Consumer $ Product DtC Marketing • Campaigns • Community • Relationships • Information Coloplast Page 52
Slide 53: Interventional Urology remains core to the Coloplast mission
Interventional Urology remains core to the Coloplast mission and value creation agenda Interventional Urology at a Glance ~15% market share in global market of DKK 13-14bn market FY 18/19 growing 3-5% annually 11% Coloplast position ENDOUROLOGY MEN’S HEALTH WOMEN’S HEALTH SPECIALTY INTERVENTIONS of
Slide 54: Interventional Urology is a DKK 12-13bn market
Interventional Urology is a DKK 12-13bn market growing 3-5% annually Business Area Market Dynamics Market Size (DKKbn) Market growth ~5 • Portfolio breadth increasingly valued Endourology ~5% • Single-use visualization significant opportunity 4 ~3 • Penile implant market responding to patient awaren
Slide 55: Interventional Urology is split into four business areas
Coloplast Interventional Urology is split into four business areas MEN’S WOMEN’S SPECIALTY ENDOUROLOGY HEALTH HEALTH INTERVENTIONS • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Tes
Slide 56: Interventional Urology competitive overview
Interventional Urology competitive overview Market presence Company Men’s Health Women’s Health Endourology Specialty Interventions ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓/ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Page 56
Slide 57: The global AWC market remains large and growing
The global AWC market remains large and growing The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and continues to grow across all regions categories and main growth contributors Market size in DKKbn RoW Silicone Foams Silicone Foam
Slide 58: In Wound Care we are progressing with our current strategy
In Wound Care we are progressing with our current strategy 1 Shape the standard Endorsements Publications Build a strong product 2 PIP portfolio 3 Accelerate in EU Ramp-up Strengthen position 4 in the US New structure New management New investment plan Secure leading position 5 in China Revised targ
Slide 59: In US Ostomy Care, we continue to gain share in acute
In US Ostomy Care, we continue to gain share in acute and have increased our focus on the home health channel US Ostomy patient pathway Continuing to gain share in the acute channel Patients +7 pts. Hospital 3-5 days 15/16 16/17 17/18 Recent acute contract wins PAC / HHA(1) ~75% of hospital >60 days
Slide 60: Introducing Ostomy Care
Introducing Ostomy Care Disease areas Key products Distribution of • Colorectal cancer (est. 45%) revenues* • Bladder cancer (est. 10%) • Diverticulitis (est. 15%) Urostomy • Inflammatory bowel disease (est. 10%) Ileostomy • Other (est. 20%) Colostomy Customer groups • Nurses, mainly stoma care nurs
Slide 61: Introducing Ostomy Care Supporting Products
Introducing Ostomy Care Supporting Products Market fundamentals Key products Brava® is a range of ostomy supporting products • Market size of DKK 2-3bn designed to reduce leakage or care for skin, to make • Market growth of 6-8% • Market share 30-35% Brava® Protective Seal our end-users feel secure.
Slide 62: Introducing Continence Care
Introducing Continence Care Disease areas Key products Distribution of • Spinal Cord Injured, SCI revenues • Spina Bifida, SB • Multiple Sclerosis, MS Intermittent catheters • Benign prostatic hyperplasia, BPH & prostatectomy patients Urine bags • Elderly Male ext. catheters Bowel management CC Othe
Slide 63: Introducing Bowel Management
Introducing Bowel Management Disease areas Market dynamics Faecal incontinence + Growing awareness (management products only) + Huge underpenetrated and Customer groups unserved population • Spinal Cord Injured, SCI + New devices addressing the many • Spina Bifida, SB unmet needs • Multiple Sclerosi
Slide 64: Introducing Interventional Urology
Introducing Interventional Urology Treatment (surgical) of urological disorders Disease areas Key products Distribution of revenues • Urinary incontinence • Pelvic organ prolapse Men’s health • Erectile dysfunction Women’s health • Enlarged prostate • Kidney and urinary stones Single use devices Cus
Slide 65: Introducing Wound Care
Introducing Wound Care Disease areas Key products Distribution of revenues Chronic wounds (WSC) • Leg ulcers Biatain® range • Diabetic foot ulcers Comfeel® range • Pressure ulcers Skin Care Wound Care other Customer groups Contract manufacturing & call points Hospitals Biatain® Silicone, incl. Sizes
Slide 66: Introducing Skin Care
Introducing Skin Care Disease areas Key products Product mix • Moisture associated skin damage Protectants & Antifungals • Incontinence Cleansing/Bathing • Skin folds & obesity Moisturizers • Prevention of skin impairments Textile SC Other Customer groups & call points Sween® EasiCleanse Bath® Hospi
Slide 67: Product market for US Skin Care
Product market for US Skin Care Market drivers/limiters US Skin Care at a glance + Aging and obese population • US market size estimated at DKK + CMS Value Based Purchasing 4-5bn with 2-4% growth + Increased focus on prevention + Increased importance of utilization • Market share: 10-15% management
Slide 68: The Coloplast organisation
The Coloplast organisation Coloplast Group Chronic Care Strategic Business Units Chronic Care Strategic Business Units Ostomy Care Continence Care Wound & Skin Care Interventional Urology Marketing Marketing Marketing Sales R&D Operations Sales Regions Sales Regions R&D Global Operations Global Busi
Slide 69: Coloplast Executive Management
Coloplast Executive Management Kristian Villumsen President, CEO • Born 1970 • With Coloplast since 2008 Anders Lonning-Skovgaard Allan Rasmussen Paul Marcun EVP, CFO EVP, Global Operations EVP, Chronic Care • Born 1972 • Born 1967 • Born 1966 • With Coloplast since 2006 • With Coloplast since 1992
Slide 70: Income statement
Income statement DKKm Q2 2018/19 Q2 2019/20 Change H1 2018/19 —_H1 2019/20 Change Revenue 4,401 4,823 10% 8,722 9,535 9% Gross profit 2,957 3,270 11% 5,860 6,482 11% SG&A costs -1472 -1,551 5% -2,910 -3,137 8% R&D costs -171 -182 6% -352 -351 0% Other operating income/expenses 28 5 -82% 41 20 -51% O
Slide 71: Balance sheet
Balance sheet DKKm 31 Mar 2019 31 Mar 2020 Change Balance, total 12,292 13,528 10% Assets Non-current assets 6,195 6,819 10% Current assets 6,097 6,709 10% of which: Inventories 1,869 1,915 2% Trade receivables 3,113 3,269 5% Amounts held in escrow 71 13 -82% Marketable securities, cash, and cash eq
Slide 72: Cash flow
Cash flow DKKm H1 2018/19 H1 2019/20 Change EBIT 2,639 3,014 14% Depreciation and amortisation 320 422 32% Change in working capital -548 -499 -9% Net interest payments -78 -128 64% Paid tax -1,012 -1,100 9% Other -87 -68 -22% Cash flow from operations 1,234 1,641 33% Investments in intangibles -36
Slide 73: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 5% Hungary 11% 2% Mørdrup China 1% Minneapolis Tatabánya Sarlat Nyirbátor US/France Mankato Denmark Zhuhai Costa Rica Costa Rica 81% COGS by cost type² 9% Salary - Direct 21% 12% Salary - Indirect Materials (RM &SFG) 8% Innovation & Specialised Pro
Slide 74: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~1,050 • Number of employees in production: ~1,800
Slide 75: Production sites
Production sites Denmark US Mørdrup Minneapolis • Pilot development work Ostomy care, • Interventional Urology products Continence care and Wound care • Number of employees in production: ~100 • Adhesives production • Number of employees in production: ~150 France Mankato • Skin care products Sarlat
Slide 76: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Ellen Bjurgert Rasmus Sørensen Hannah Katrine Larsen Vice President, Investor Relations Senior Manager, Investor Relations Investor Relations Coordinator & PA Tel. direct: +45 4911 3376 Tel. direct: +45 4911 1786 Tel. direct: +45 4911 36
Slide 77: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /